In the context of BRFAA’s preclinical expertise on existing/established drugs, services are provided for drug repositioning computational studies preferably to sponsors which will present well-documented projects with specific proposals. The process includes initial Proof-of-Concept studies at the preclinical level in order to investigate:
- Route of administration
- New target engagement of the existing drugs and
- in vivo efficacy
Main goal is to build up a data package for clinical evaluation.